Erna

ANTHROPOGENIC AND EQO PARTNER TO ENABLE GROUNDBREAKING BIODIVERSITY-LINKED FINANCIAL INTELLIGENCE

Retrieved on: 
Wednesday, October 18, 2023
Biodiversity, Biotechnology, Environmental health, Erna, Environment, Trust, CIO, The Environment Trust (Tower Hamlets), Partnership, Life-support system, Investment, Edna, Agriculture, Risk management

BOSTON, Oct. 18, 2023 /PRNewswire/ -- In a landmark collaboration, Anthropogenic Inc. and EQO have unveiled plans to pioneer a new generation of financial products that seamlessly integrate biodiversity data into the financial world.

Key Points: 
  • BOSTON, Oct. 18, 2023 /PRNewswire/ -- In a landmark collaboration, Anthropogenic Inc. and EQO have unveiled plans to pioneer a new generation of financial products that seamlessly integrate biodiversity data into the financial world.
  • This collaboration allows the unique genomic capabilities of EQO's eRNA and eDNA technology to monitor the real-world impacts on biodiversity stemming from various financial assets, all powered by the Anthropogenic platform.
  • - Dr. Harmony Martell, Scientific Advisor, EQO, Inc.
    By seamlessly integrating biodiversity considerations into financial decision-making, Anthropogenic and EQO aspire to propel positive change on a global scale.
  • This strategic alliance underscores a shared vision for a sustainable financial future, where Anthropogenic and EQO are at the forefront of fostering a dynamic equilibrium between financial prowess and meaningful contributions to biodiversity conservation.

RNA Therapeutics Market Poised for Explosive Growth: Estimated Worth Exceeds $1.1 Billion by 2035, with a Remarkable 50% CAGR from 2026-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Transfer, Gene expression, Vaccine, Infection, Investment, Vertex Pharmaceuticals, Engineering, Sarcoidosis, RNA, USD, Therapy, Safety, SaRNA, Cystic fibrosis, Attenuated vaccine, Erna, Duchenne muscular dystrophy, Recode, Messenger, Circular RNA, Small RNA, China-ASEAN Investment Cooperation Fund, RNA therapeutics, Research, Pharmaceutical industry

The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.
  • Next Generation RNA Therapeutics and Vaccines: The market is witnessing the development of next-generation RNA therapeutics and vaccines that target diseases previously considered undruggable.
  • These include modalities such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA).
  • Investment and Funding: The market has attracted substantial investments, with over $2.9 billion raised or invested in RNA therapeutics and RNA vaccines development since 2019.

Laronde Announces New Leadership

Retrieved on: 
Monday, May 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Vaccine, Erna, Therapy, Gene editing, Medicine, RNA, Antibody, Translation, Protein, Patient, Drug discovery, Rare, Management, Pharmaceutical industry, LaRonde mine

Laronde also announced the appointment of Trevor J. Hallam, Ph.D., as Chief Scientific Officer, effective May 15, 2023.

Key Points: 
  • Laronde also announced the appointment of Trevor J. Hallam, Ph.D., as Chief Scientific Officer, effective May 15, 2023.
  • Dr. Hallam joins Laronde from Sutro Biopharma, where he was President of Research and Chief Scientific Officer.
  • “Laronde is an incredible company and I believe that our eRNA platform has the potential to create an entirely new class of medicines across several therapeutic areas,” said Pablo J. Cagnoni, M.D., Chief Executive Officer of Laronde.
  • “I am thrilled to work alongside John, Avak, and the entire team in place at Laronde and to continue to explore the vast potential of eRNA.”

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Rubius, Inflammation, Erna, Amgen, Gilead Sciences, Pediatric Hematology and Oncology, Drug development, University, Onyx, El Rubius, Cancer, Autoimmunity, RNA, Mount Sinai Medical Center, Onyx Pharmaceuticals, Haematopoietic system, Organization, Chemistry, Senior, Investigational New Drug, Patient, Biology, R, Therapy, Pharmaceutical industry, Oncology, Hematology, Dermatology, Medicine

Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.
  • President and Head of Research & Development (R&D) effective June 5, 2023.
  • “This newly created role integrates chemistry, biology and development with the goal of maximizing the impact of our portfolio and accelerating our innovative pipeline,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “Incyte has a strong foundation of bringing first-in-class treatments to patients and I am honored to join the organization,” said Dr. Cagnoni.

Mats Danielsson receives the Hans Wigzell Research Foundation's science prize amounting to SEK 925,000.

Retrieved on: 
Thursday, December 8, 2022
Rolf Schock Prizes, Danielsson, Physics, Degenerative disease, Swedish Medical Society, Science, KI, KTH Royal Institute of Technology, Diagnosis, Swedish Foundation for Strategic Research, Karolinska Institute, Department of Engineering Science, University of Oxford, IVA, Cancer, Royal Swedish Academy of Sciences, Research, Infectious Diseases Institute, Nobel Committee, CERN, Silicon, Swedish Research Council, Royal Academy of Arts, Value Partners (asset management), Erna, Education, Research Foundation – Flanders (FWO), Organization, Electronics, SEK, Risk, Pharmaceutical industry, Medical imaging, EU

STOCKHOLM, Dec. 8, 2022 /PRNewswire/ -- The Hans Wigzell's Research Foundation awards its annual scientific prize, to Professor Mats Danielsson at the KTH Royal Institute of Technology in Stockholm.

Key Points: 
  • STOCKHOLM, Dec. 8, 2022 /PRNewswire/ -- The Hans Wigzell's Research Foundation awards its annual scientific prize, to Professor Mats Danielsson at the KTH Royal Institute of Technology in Stockholm.
  • Professor Mats Danielsson receives the prize of SEK 925,000 for his research around medical imaging technology, a technology that can enable earlier diagnosis of cancer and cardiovascular diseases.
  • Mats Danielsson leads a research group at KTH Royal Institute of Technology in physics of medical imaging.
  • Mats Danielsson has a background as a particle physicist and wrote his dissertation on a thesis based on research at CERN.

Laronde Appoints Pablo J. Cagnoni as Chief Executive Officer

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Genetics, Health, Rubius, Onyx Pharmaceuticals, Onyx, Biotechnology Innovation Organization, Amgen, Cell, Council, Flagship Pioneering, L-Ribonucleic acid aptamer, Trustee, Mount Sinai Medical Center, Drug development, Bay Area Discovery Museum, El Rubius, Therapy, Haematopoietic system, OSI Pharmaceuticals, Gilead Sciences, Spectrum Pharmaceuticals, CRISPR Therapeutics, Medicine, Cancer, Life, BIO, Flagship, Investigational New Drug, Immune system, RNA, Development, Protein, Biology, Allos, University, Assistant, Health, MD, Patient, Erna, Pediatric Hematology and Oncology, Management, Pharmaceutical industry, Vaccine, Giselle Laronde, Astellas Pharma, Hematology

Laronde is an exceptional company built on a truly unique platform with the potential to change the way we approach medicine, said Pablo J. Cagnoni, MD, Chief Executive Officer, Laronde and Executive Partner, Flagship Pioneering.

Key Points: 
  • Laronde is an exceptional company built on a truly unique platform with the potential to change the way we approach medicine, said Pablo J. Cagnoni, MD, Chief Executive Officer, Laronde and Executive Partner, Flagship Pioneering.
  • Dr. Cagnoni most recently served as President and Chief Executive Officer of Rubius Therapeutics.
  • Before joining Rubius in 2018, Dr. Cagnoni served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer.
  • From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022
LinkedIn, RNA transfection, Therapy, Drug resistance, Professional services, Publication, R, Journalism, Lung cancer, Inflammation, Autoimmunity, Solution, Final good, Erna, News, Lung, Instability, NYSE, Tissue, Invention, Industry, Breast cancer, IP, SMOP, Fibrosis, Listeria monocytogenes non-coding RNA, Ownership, Pharma, Health care, Organization, Intelligence, Research, Cell, Technology, Degenerative disease, FALCON, Clarivate, CNS, Web of Science, Intellectual property, OSCAR, Traction, Disease, Oligonucleotide, Patient, ASO, RNA, Kidney, Report, Sirna, Wisper, Liver, Academy, COVID-19, Lead, List of life sciences, Pharmaceutical industry, Vaccine

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022
LinkedIn, RNA transfection, Therapy, Drug resistance, Professional services, Publication, R, Journalism, Lung cancer, Inflammation, Autoimmunity, Solution, Final good, Erna, News, Lung, Instability, NYSE, Tissue, Invention, Industry, Breast cancer, IP, SMOP, Fibrosis, Listeria monocytogenes non-coding RNA, Ownership, Pharma, Health care, Organization, Intelligence, Research, Cell, Technology, Degenerative disease, FALCON, Clarivate, CNS, Web of Science, Intellectual property, OSCAR, Traction, Disease, Oligonucleotide, Patient, ASO, RNA, Kidney, Report, Sirna, Wisper, Liver, Academy, COVID-19, Lead, List of life sciences, Pharmaceutical industry, Vaccine

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

Laronde Appoints John Mendlein as Chief Executive Officer

Retrieved on: 
Thursday, August 4, 2022
Aurora, Multimedia, Johnson & Johnson, CEO, Aurora Biosciences, Senda, Ecosystem, Growth, John Mendlein, Board, Director, Debiopharm, Life, Therapy, Cell, Erna, Twitter, RNA, Drug development, Biology, Omega, Publication, Protein, Flagship Pioneering, LinkedIn, Medicine, Immune system, Vertex Pharmaceuticals, Vaccine, Pharmaceutical industry, Management, Flagship, Giselle Laronde, Moderna

D., the company's Chairman, will become its interim Chief Executive Officer, effective this month.

Key Points: 
  • D., the company's Chairman, will become its interim Chief Executive Officer, effective this month.
  • Mendlein succeeds Diego Miralles, M.D., who joined Laronde as CEO in December 2020 from Vividion Therapeutics, Inc. and Johnson & Johnson in San Diego.
  • "I look forward to my continuing role engaging with Flagship as an Advisor and am grateful for my time at Laronde and wish John all the best in his new role."
  • John Mendlein is an executive partner at Flagship Pioneering, contributing to Flagship's strategic and operational objectives, including the origination of new Flagship Labs companies.

Laronde Expands Board of Directors with Leading Pharmaceutical Executives

Retrieved on: 
Monday, November 1, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Rubius, Biology, Research, Chemistry, Technology, University, LinkedIn, Spectrum Pharmaceuticals, Mount Sinai Medical Center, Cancer, Drug development, Vice, Twitter, OSI Pharmaceuticals, Fortune, Patient, Forbes, Hematology, J&J, Gilead Sciences, RNA, Rutgers University, Haematopoietic system, Amgen, University of Massachusetts Dartmouth, Stryker, Life, Flagship Pioneering, Johnson & Johnson, Endless, Chemical engineering, EQT Partners, Erna, Cell, L-Ribonucleic acid aptamer, Onyx Pharmaceuticals, Woman, Therapy, Immune system, AstraZeneca, Princeton University, Chief executive officer, Pharmaceutical industry, Vaccine, Endless RNA™, Laronde, ENDLESS RNA™, LARONDE

have been appointed to the companys board of directors.

Key Points: 
  • have been appointed to the companys board of directors.
  • Together, they bring deep experience driving research, development, and commercialization of life-saving medicines from some of the most prestigious global pharmaceutical companies.
  • On the heels of our successful Series B financing, we are excited to welcome Pablo and Sheri to our board of directors.
  • Im excited to join the board at this pivotal time to explore new and innovative ways to treat complex diseases.